The long term objective of the Northern Indiana Cancer Research Consortium (NICRC) is to promote community participation in National Cancer Institute (NCI) sponsored clinical trials in Indiana and Michigan. This includes promotion of both cancer control and treatment studies. Six hospitals and a variety of physicians including oncologists, surgeons, specialists, and primary care physicians have come together to support this endeavor and to build on each others resources and outreach efforts in order to bring the best care to all community residents. When treating cancer, physicians have to consider numerous factors in addition to the best treatment options available. Quality of life, insurance, cost, and time constraints are just some of the elements involved with cancer treatment. Receiving treatment close to home provides patients with improved quality of life, decreased travel costs, and additional time to spend with family and friends. Through the CCOP, the NICRC is able to provide the best treatment options while allowing patients to receive treatment in their home communities. The science that is learned from participation in clinical trials is invaluable in the fight to cure cancer and the ability for patients to receive treatment close to home is priceless. In addition to treating cancer, the NICRC is also dedicated to increasing public awareness about cancer and early detection. Through cancer control studies, newspaper articles and public broadcast announcements, the NICRC hopes to decrease the incidence and mortality of cancer in Indiana and Michigan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA086726-13
Application #
8320008
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
2000-09-28
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
13
Fiscal Year
2012
Total Cost
$802,879
Indirect Cost
$270,882
Name
Memorial Hospital of South Bend
Department
Type
DUNS #
064701261
City
South Bend
State
IN
Country
United States
Zip Code
46601
Pradhan, Kamnesh R; Stump, Timothy E; Monahan, Patrick et al. (2015) Relationships among attention function, exercise, and body mass index: a comparison between young breast cancer survivors and acquaintance controls. Psychooncology 24:325-32
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Werner, Benjamin; Gallagher, Robert E; Paietta, Elisabeth M et al. (2014) Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia. Cancer Res 74:5386-96
Champion, Victoria L; Wagner, Lynne I; Monahan, Patrick O et al. (2014) Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains. Cancer 120:2237-46
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Burstein, Harold J; Cirrincione, Constance T; Barry, William T et al. (2014) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women J Clin Oncol 32:3959-66
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20
Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17

Showing the most recent 10 out of 23 publications